187 related articles for article (PubMed ID: 38278976)
1. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Lito P; Solomon M; Li LS; Hansen R; Rosen N
Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430
[TBL] [Abstract][Full Text] [Related]
3. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
5. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
6. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
[TBL] [Abstract][Full Text] [Related]
7. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
8.
Sealover NE; Theard PT; Hughes JM; Linke AJ; Daley BR; Kortum RL
iScience; 2024 Jan; 27(1):108711. PubMed ID: 38226159
[TBL] [Abstract][Full Text] [Related]
9. TEAD Inhibitors Sensitize KRAS
Tammaccaro SL; Prigent P; Le Bail JC; Dos-Santos O; Dassencourt L; Eskandar M; Buzy A; Venier O; Guillemot JC; Veeranagouda Y; Didier M; Spanakis E; Kanno T; Cesaroni M; Mathieu S; Canard L; Casse A; Windenberger F; Calvet L; Noblet L; Sidhu S; Debussche L; Moll J; Valtingojer I
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111311
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.
Lee C; Jiang ZK; Planken S; Manzuk LK; Ortiz R; Hall M; Noorbehesht K; Ram S; Affolter T; Troche GE; Ihle NT; Johnson T; Ahn Y; Kraus M; Giddabasappa A
Mol Cancer Ther; 2023 Jul; 22(7):891-900. PubMed ID: 37186518
[TBL] [Abstract][Full Text] [Related]
11. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
Hoshiyama H
Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
[TBL] [Abstract][Full Text] [Related]
13. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
14. Acquired Resistance to KRAS
Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
[TBL] [Abstract][Full Text] [Related]
15. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura S; Mzannar Y; Azar I; Beal E; Tobon M; Kim S; Beydoun R; Baloglu E; Senapedis W; El-Rayes B; Philip PA; Mohammad RM; Shields AF; Al-Hallak MN; Azmi AS
bioRxiv; 2023 Mar; ():. PubMed ID: 37034616
[TBL] [Abstract][Full Text] [Related]
16. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
17. Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma.
Ramalingam PS; Priyadharshini A; Emerson IA; Arumugam S
Front Med (Lausanne); 2023; 10():1107128. PubMed ID: 37396909
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ULK1/2 and KRAS
Ghazi PC; O'Toole KT; Srinivas Boggaram S; Scherzer MT; Silvis MR; Zhang Y; Bogdan M; Smith BD; Lozano G; Flynn DL; Snyder EL; Kinsey CG; McMahon M
bioRxiv; 2024 Feb; ():. PubMed ID: 38370808
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the Therapeutic Efficacy of KRAS
Liu Y; Wu L; Lu H; Wu E; Ni J; Zhou X
J Oncol; 2021; 2021():2721466. PubMed ID: 34858498
[TBL] [Abstract][Full Text] [Related]
20. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]